Clearmind Medicine

Company Overview

Snapshot

Founded in January 2021, Clearmind Medicine operates with 1–10 employees and has raised a total of $16.21 million across six funding rounds. The company became public on NASDAQ in November 2022.

Business overview

Clearmind Medicine is a Health Tech & Life Sciences company focused on developing treatments for binge behavior and mental health conditions, including alcohol use disorder, binge eating, and depression. Its core product, MEAI, is designed to provide a euphoric, alcohol-like experience while reducing the desire for alcohol consumption. The company operates within the Pharma & Medical Biotechnology sector, specifically in Drugs Discovery & Development, targeting healthcare and laboratory markets with its biological molecules.

Strategic signal

In November 2025, Clearmind Medicine announced positive top-line results from the first cohort of its FDA-approved Phase I/IIa clinical trial for CMND-100, a treatment for Alcohol Use Disorder. This milestone indicates significant progress in the company's clinical development pipeline and provides validation for its psychedelic-derived therapies, signaling potential for future advancements in addressing critical mental health challenges.

Company Intelligence Q&A

When did Clearmind Medicine go public on NASDAQ?

Clearmind Medicine became public on NASDAQ in November 2022, following a public offering that raised $7.5 million.

What is the status of Clearmind Medicine's clinical trials for Alcohol Use Disorder?

In November 2025, Clearmind Medicine announced positive top-line results from the first cohort of its FDA-approved Phase I/IIa clinical trial for CMND-100, a treatment for Alcohol Use Disorder. The Data and Safety Monitoring Board unanimously approved the continuation of the trial after a positive interim safety review.

Has Clearmind Medicine expanded its intellectual property for depression treatment?

In November 2025, Clearmind Medicine expanded its global IP protection for MEAI in depression treatment with a new South Korea patent filing. Additionally, in November 2025, Neurothera Labs announced an Israeli patent application in collaboration with Clearmind Medicine for a novel non-hallucinogenic neuroplastogen treatment for depression.

What is Clearmind Medicine's strategy regarding its clinical trial sites?

In November 2025, Clearmind Medicine accelerated its FDA-approved Alcohol Use Disorder clinical trial by activating a fifth elite global medical site. The company also received final approval in November 2025 to expand its FDA-regulated Phase I/IIa clinical trial for Alcohol Use Disorder at Hadassah Medical Center.